VistaGen Therapeutics (VTGN)
(Real Time Quote from BATS)
$4.65 USD
-0.07 (-1.48%)
Updated Apr 25, 2024 11:00 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for VistaGen Therapeutics, Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 17 | 68 | 103 | 1 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 3 | 1 | 0 |
Total Current Assets | NA | 18 | 71 | 104 | 2 |
Net Property & Equipment | NA | 1 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 1 | 0 | 1 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 21 | 75 | 108 | 6 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 3 | 1 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 1 | 1 | 2 | 1 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 1 | 1 | 0 |
Total Current Liabilities | NA | 5 | 6 | 4 | 3 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 2 | 2 | 2 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 6 | 5 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 9 | 10 | 16 | 12 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 343 | 336 | 316 | 200 |
Retained Earnings | NA | -327 | -268 | -220 | -202 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 4 | 4 | 4 | 4 |
Total Shareholder's Equity | NA | 12 | 65 | 92 | -6 |
Total Liabilities & Shareholder's Equity | NA | 21 | 75 | 108 | 6 |
Total Common Equity | 0 | 12 | 65 | 92 | -6 |
Shares Outstanding | 27.00 | 7.30 | 6.80 | 6.00 | 1.60 |
Book Value Per Share | 0.00 | 1.65 | 9.52 | 15.33 | -3.58 |
Fiscal Year End for VistaGen Therapeutics, Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 127 | 38 | 10 | 17 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 2 | 1 | 2 | 1 |
Total Current Assets | NA | 128 | 39 | 12 | 18 |
Net Property & Equipment | NA | 0 | 0 | 0 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 1 | 1 | 1 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 131 | 42 | 15 | 21 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 1 | 0 |
Accounts Payable | NA | 2 | 1 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 1 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 2 | 1 | 1 | 1 |
Total Current Liabilities | NA | 4 | 3 | 4 | 5 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 2 | 2 | 2 | 2 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 8 | 7 | 8 | 9 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 474 | 380 | 345 | 343 |
Retained Earnings | NA | -347 | -340 | -334 | -327 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 4 | 4 | 4 | 4 |
Total Shareholder's Equity | NA | 123 | 36 | 7 | 12 |
Total Liabilities & Shareholder's Equity | NA | 131 | 42 | 15 | 21 |
Total Common Equity | 0 | 123 | 36 | 7 | 12 |
Shares Outstanding | 27.00 | 27.00 | 12.00 | 7.90 | 7.30 |
Book Value Per Share | 0.00 | 4.57 | 2.97 | 0.87 | 1.65 |